Eileen M. O’Reilly, MD, expands on the updated survival data from NAPOLI-3, explains how NALIRIFOX could fit into the current pancreatic ductal adenocarcinoma treatment paradigm, and shares potential opportunities to build upon this research moving forward.
ctDNA negative status contributes to positive outcomes for DLBCL healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Responses achieved with enfortumab vedotin plus pembrolizumab were found to be rapid and durable in patients with previously untreated locally advanced or metastatic urothelial carcinoma who were cisplatin ineligible.
CHICAGO — Pembrolizumab plus axitinib continued to confer a survival benefit vs. sunitinib at 5-year follow-up as first-line therapy for patients with advanced clear cell renal cell carcinoma, according to study results. The long-term data, presented at ASCO Annual Meeting, showed improved outcomes with the combination even though more patients in the sunitinib group had subsequent